{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T12:08:37Z","timestamp":1767182917141,"version":"3.44.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RC-2024-2790136"],"award-info":[{"award-number":["RC-2024-2790136"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.esmoop.2025.105300","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T08:04:52Z","timestamp":1751011492000},"page":"105300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development of a risk score based on clinical\u2013pathological features to predict the presence of germline BRCA1\/2 pathogenic variants in ovarian cancer patients"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6909-2412","authenticated-orcid":false,"given":"G.","family":"Innella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Erini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"De Leo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Godino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Caramanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8493-6230","authenticated-orcid":false,"given":"S.","family":"Miccoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"De Iaco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Turchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Rucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmoop.2025.105300_bib1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105300_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2025.105300_bib3","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/318787","article-title":"Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer","volume":"68","author":"Risch","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.esmoop.2025.105300_bib4","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation\u2013positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study group","volume":"30","author":"Alsop","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105300_bib5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ygyno.2017.08.030","article-title":"Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls","volume":"147","author":"Lilyquist","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105300_bib6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2025.105300_bib7","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3390\/cancers10120487","article-title":"Role of BRCA mutations in cancer treatment with poly(ADP-ribose) polymerase (PARP) inhibitors","volume":"10","author":"Faraoni","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105300_bib8","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.6004\/jnccn.2023.0051","article-title":"NCCN guidelines\u00ae insights: genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2024","volume":"21","author":"Daly","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105300_bib9","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105300_bib10","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/cancers10110435","article-title":"Next-generation service delivery: a scoping review of patient outcomes associated with alternative models of genetic counseling and genetic testing for hereditary cancer","volume":"10","author":"McCuaig","year":"2018","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105300_bib11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/ajco.13334","article-title":"Mainstream consent programs for genetic counseling in cancer patients: a systematic review","volume":"17","author":"Scheinberg","year":"2021","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105300_bib12","article-title":"Cancer genetic services in a low- to middle-income country: cross-sectional survey assessing willingness to undergo and pay for germline genetic testing","volume":"9","author":"Adejumo","year":"2023","journal-title":"JCO Glob Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105300_bib13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.6004\/jnccn.2022.7257","article-title":"Nationwide trends and determinants of germline BRCA1\/2 testing in patients with breast and ovarian cancer","volume":"21","author":"Lau-Min","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105300_bib14","doi-asserted-by":"crossref","first-page":"202","DOI":"10.31083\/j.ejgo4302026","article-title":"BRCA screening, treatment patterns and response among patients with ovarian cancer in the second line treatment setting: results from a real world survey","volume":"43","author":"Monberg","year":"2022","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.esmoop.2025.105300_bib15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ygyno.2023.03.016","article-title":"Outcomes of the \u201cBRCA Quality Improvement Dissemination Program\u201d: an initiative to improve patient receipt of cancer genetics services at five health systems","volume":"172","author":"Bednar","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105300_bib16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13053-022-00238-w","article-title":"Mainstream genetic testing for women with ovarian cancer provides a solid basis for patients to make a well-informed decision about genetic testing","volume":"20","author":"Bokkers","year":"2022","journal-title":"Hered Cancer Clin Pract"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105300_bib17","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/s41436-021-01262-2","article-title":"Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer","volume":"23","author":"Hamilton","year":"2021","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105300_bib18","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10689-015-9852-6","article-title":"Non-genetic health professionals\u2019 attitude towards, knowledge of and skills in discussing and ordering genetic testing for hereditary cancer","volume":"15","author":"Douma","year":"2016","journal-title":"Fam Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105300_bib19","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/jcp-2022-208753","article-title":"Factors predicting BRCA1\/2 pathogenic variants in patients with ovarian cancer: a systematic review with meta-analysis","volume":"76","author":"Innella","year":"2023","journal-title":"J Clin Pathol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105300_bib20","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1002\/cam4.2824","article-title":"A regional population-based hereditary breast cancer screening tool in Italy: first 5-year results","volume":"9","author":"Cortesi","year":"2020","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105300_bib21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/mps7040063","article-title":"Evaluation of an Italian population-based programme for risk assessment and genetic counselling and testing for BRCA1\/2-related hereditary breast and ovarian cancer after 10 years of operation: an observational study protocol","volume":"7","author":"Ferretti","year":"2024","journal-title":"Methods Protoc"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105300_bib22","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3390\/diagnostics11040697","article-title":"What is new on ovarian carcinoma: integrated morphologic and molecular analysis following the new 2020 World Health Organization classification of female genital tumors","volume":"11","author":"De Leo","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105300_bib23","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1136\/jmg-2023-109694","article-title":"Clinical implications of VUS reclassification in a single-centre series from application of ACMG\/AMP classification rules specified for BRCA1\/2","volume":"61","author":"Innella","year":"2024","journal-title":"J Med Genet"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105300_bib24","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ajhg.2024.07.013","article-title":"Evidence-based recommendations for gene-specific ACMG\/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel","volume":"111","author":"Parsons","year":"2024","journal-title":"Am J Hum Genet"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105300_bib25","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1158\/1055-9965.EPI-20-1319","article-title":"CanRisk tool-a web interface for the prediction of breast and ovarian cancer risk and the likelihood of carrying genetic pathogenic variants","volume":"30","author":"Carver","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"suppl 8","key":"10.1016\/j.esmoop.2025.105300_bib26","doi-asserted-by":"crossref","first-page":"viii69","DOI":"10.1093\/annonc\/mdt312","article-title":"Variants of unknown significance in BRCA testing: impact on risk perception, worry, prevention and counseling","volume":"24","author":"Richter","year":"2013","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105300_bib27","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1086\/424388","article-title":"Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2","volume":"75","author":"Goldgar","year":"2004","journal-title":"Am J Hum Genet"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292501169X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292501169X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T06:00:53Z","timestamp":1755496853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292501169X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S205970292501169X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105300","relation":{},"ISSN":["2059-7029"],"issn-type":[{"type":"print","value":"2059-7029"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a risk score based on clinical\u2013pathological features to predict the presence of germline BRCA1\/2 pathogenic variants in ovarian cancer patients","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105300","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105300"}}